News from the FDA/CDC
Latest News
FDA to step up oversight of cosmetics, assess ‘forever chemicals’
The cosmetic products include makeup products, nail polishes, shaving creams, other grooming products, perfumes, face and body cleansers, hair...
Latest News
More children missing developmental milestones: Survey
No significant change was seen from 2019 to 2021 in how common it was for survey respondents to report children having autism or an intellectual...
FDA/CDC
FDA clears new biomarker assays for early Alzheimer’s detection
Currently, the only FDA-cleared methods to confirm amyloid pathology are CSF tests and PET scans.
FDA/CDC
FDA panel unanimously endorses lecanemab for Alzheimer’s
An intravenous infusion targeting amyloid-beta, lecanemab received accelerated FDA approved earlier in 2023 for the treatment of early Alzheimer’s...
FDA/CDC
FDA gives fast-track approval to new ALS drug
“The FDA’s approval of Qalsody gives me hope that people living with this rare form of ALS could experience a reduction in decline in strength,...
News from the FDA/CDC
FDA approves OTC naloxone, but will cost be a barrier?
“The major question is what is it going to cost. In order for people to access it they have to be able to afford it,”
News from the FDA/CDC
New report says suicide rates rising among young Black people
Significant increases in suicide occurred among Native American, Black and Hispanic people.
News from the FDA/CDC
Alzheimer’s Association to CMS: Ditch restraints on amyloid drugs
The CMS coverage restrictions for anti-amyloid drugs were finalized in April on the...
News from the FDA/CDC
CDC warns of enterovirus strain linked to polio-like condition
The advisory also urged providers to “strongly consider AFM in patients with acute flaccid limb weakness, especially after respiratory illness or...
News from the FDA/CDC
COVID to blame as U.S. life expectancy falls
The overall drop took national life expectancy from 78.8 years in 2019 to 77 years in 2020.
News from the FDA/CDC
FDA grants emergency authorization for Novavax COVID vaccine
Clinical trials found the vaccine to be 90.4% effective in preventing mild, moderate or severe COVID-19.